Panel · Use case · Regulatory

Conditional Approval Conversion Review.

LiveBenefit-Risk Panel

The confirmatory evidence is in. Does it convert the conditional approval to a full one, and has the balance shifted?

DecisionWhether the confirmatory evidence converts the approval

FunctionsRegulatory, evidence, access, ecosystem

ReaderRegulatory and access leads

Not askedA filing

DepthStandard, four seats

Conditional Approval Conversion Review is a ready-made use case for Regulatory. It ships under the Benefit-Risk Panel template.

For access and policy leads. You get the effects table, each seat's conclusion, the weighing matrix, the uncertainties and the risk-minimisation measures. Claims are cited or marked as gaps.

Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.

The decision

The confirmatory evidence is in. Does it convert the conditional approval to a full one, and has the balance shifted?

Who weighs

A conditional approval rests on an obligation to provide confirmatory evidence. In the EU a conditional marketing authorization is renewed yearly until the obligations are met, and in the US an accelerated approval requires confirmatory trials.

Seat	What it weighs	What it works from
VP Global Regulatory Strategy	Whether the obligation is met and the route to conversion.^{1European Medicines Agency. Conditional marketing authorisation.,2U.S. Food and Drug Administration. Accelerated Approval Program.}	EMA conditional authorization and FDA accelerated approval.
Global Value & Evidence Lead	How the confirmatory result compares with the earlier surrogate or interim result.	The confirmatory study report.
Global Market Access Director	Whether payers who accepted the early evidence will revise their view.	Payer decisions.
Ecosystem Intelligence Orchestrator	What competitors and societies have said since approval.	Public record.

What the assessment does

The balance is re-read with new data. The effects table shows each effect as estimated at approval and as estimated in the confirmatory data, with the change and what it implies.^{1European Medicines Agency. Conditional marketing authorisation.,2U.S. Food and Drug Administration. Accelerated Approval Program.}

A shift can go either way. The confirmatory result may confirm, narrow or contradict the early evidence. The report states which, and for which effects.

Payers are a second audience. Coverage decisions made on early evidence may be revisited. The report notes which payers set conditions for their decisions.

Recommended length

Standard

Four functions read the effects differently. Standard depth gives each a seat and shows the weighing matrix and the risk minimization table in about four pages.

You can pick another length on the form. The other two stay available.

Assumptions the assessment makes

The assessment states what it assumes about the evidence and the setting, and says what each gap limits. Examples for this decision:

The confirmatory population matches the one in the approval.
The endpoint in the confirmatory trial is the one the obligation named.
The agency will treat the result as meeting the obligation.

Standards, guidance and sources

Frame

EMA, conditional marketing authorisation.^{1European Medicines Agency. Conditional marketing authorisation.}
FDA, accelerated approval program.^{2U.S. Food and Drug Administration. Accelerated Approval Program.}

The decision practice behind the memo itself is on the template page.

What gets flagged

Any effect reported as confirmed where the confirmatory data differ, any payer view not sourced, and any obligation not specified in the approval.

What arrives

Decision and therapeutic context
Benefit-risk conclusion
Effects table
What each seat concludes
Weighing matrix by seat and criterion
Uncertainties and sensitivity
Risk minimisation and monitoring
What would change the balance

What it will not do

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists, and the decision stays with you.

It does not predict an agency decision.

It does not replace a regulator or a benefit-risk committee. The conclusion is analyst judgment from AI specialists.

It does not compute a single benefit-risk score or invent patient preferences.

It does not add an effect that no source supports. Missing data are marked as gaps.

References

[1] European Medicines Agency. Conditional marketing authorisation. Known from EMA’s site; the page was not opened in this pass.
[2] U.S. Food and Drug Administration. Accelerated Approval Program. Known from FDA’s site; not read in full.

Links checked 9 October 2026

These are the sources the template drew on. None of their authors or issuers has reviewed it.

About the Panel service

Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.

To edit a saved template, open New → Panel → From template, or the library rail on the service form.